Yanira Martinez Claudio, FNP-C | |
141 N 6th St, Haines City, FL 33844-4207 | |
(863) 353-1538 | |
Not Available |
Full Name | Yanira Martinez Claudio |
---|---|
Gender | Female |
Speciality | Clinical Nurse Specialist - Family Health |
Location | 141 N 6th St, Haines City, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1992561831 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364SF0001X | Clinical Nurse Specialist - Family Health | 11031507 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Yanira Martinez Claudio, FNP-C 4545 Pleasant Hill Rd Ste 112, Kissimmee, FL 34759-3400 Ph: () - | Yanira Martinez Claudio, FNP-C 141 N 6th St, Haines City, FL 33844-4207 Ph: (863) 353-1538 |
News Archive
QuadraMed® Corporation, a leading provider of healthcare information technologies and services that help turn quality care into positive financial outcomes, today announced the launch of its ICD-10 Countdown Program. This new program includes the Quantim® ICD-10 Coding Simulator software, ICD-10 educational tools and services to guide healthcare providers through the ICD-10 conversion.
Astex Pharmaceuticals, Inc, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.
Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin.
Dena S. Cox, professor of marketing and faculty fellow at the Kelley School of Business Indianapolis, has received a $99,600, two-year research grant from Merck to study factors influencing young women's adoption of the human papillomavirus (HPV) vaccine.
› Verified 7 days ago